+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

2019 Chronic Thromboembolic Pulmonary Hypertension Clinical Trials Guide- Companies, Drugs, Phases, Subjects, Current Status and Outlook to 2025

  • ID: 4767786
  • Report
  • 50 pages
  • VPA Research
1 of 4

FEATURED COMPANIES

  • Bayer AG
  • Gilead Sciences Inc
  • GlaxoSmithKline Plc
  • Johnson & Johnson
  • Nippon Shinyaku Co Ltd
  • Promedica International
  • MORE
The global clinical trial report- “2019 Chronic Thromboembolic Pulmonary Hypertension Clinical Trials Study” provides complete list of trials completed, ongoing and planned for Chronic Thromboembolic Pulmonary Hypertension. It presents in-depth analysis of Chronic Thromboembolic Pulmonary Hypertension clinical trials across markets and companies. The research work is for providing complete understanding into trends in Chronic Thromboembolic Pulmonary Hypertension.

The report covers a key snapshot of trial trends, enrollment trends, success trends, locations and other trends.

It also segments the Chronic Thromboembolic Pulmonary Hypertension clinical trials by:
  • Current Trial Status
  • Type of the trial
  • Sponsor Type
  • Enrollment Trends
  • Region
  • Countries
  • Trial Phase
The report also identifies the potential drug candidates under development for treatment of Chronic Thromboembolic Pulmonary Hypertension

The research work is prepared through extensive and continuous research on Chronic Thromboembolic Pulmonary Hypertension trials from over 1500 sources including company websites, conferences and presentations, scientific journals, country wise and global clinical trial registries, news, health and science departments among others.

Report Scope and Coverage:
  • All major trials from 2010 to 2019 and planned trials are included in the report scope.
  • Drug candidates currently being researched for administering Chronic Thromboembolic Pulmonary Hypertension patients are identified
  • The report includes panorama of Chronic Thromboembolic Pulmonary Hypertension clinical trials across the globe
  • Trial Phase, Current Status, Sponsor Type, Location, trial type and Enrollment details are provided
  • Companies and universities focusing on Chronic Thromboembolic Pulmonary Hypertension clinical trials are analyzed along with their trial participation (trial title, trial phase and current status)
  • Average Enrollment number, insights into enrollment trends, company wise enrollment are included
  • Both interventional and observational studies are analyzed
  • News and latest developments for the past one year are presented in the report
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Bayer AG
  • Gilead Sciences Inc
  • GlaxoSmithKline Plc
  • Johnson & Johnson
  • Nippon Shinyaku Co Ltd
  • Promedica International
  • MORE
1.1 List of Figures
1.2 List of Tables

2. Executive Summary
2.1 Chronic Thromboembolic Pulmonary Hypertension Clinical Trials Overview, 2019
2.2 Premium Insights into Clinical Trials
2.2.1 Chronic Thromboembolic Pulmonary Hypertension Clinical Trials by Region
2.2.2 Average Enrollment of Chronic Thromboembolic Pulmonary Hypertension Clinical Trials
2.2.3 Companies participating in Trials
2.2.4 Drugs under Study for Chronic Thromboembolic Pulmonary Hypertension Treatment, 2019

3. Region wise Chronic Thromboembolic Pulmonary Hypertension Clinical Trials
3.1 Asia Pacific Chronic Thromboembolic Pulmonary Hypertension Clinical Trials by Country
3.2 Europe Chronic Thromboembolic Pulmonary Hypertension Clinical Trials by Country
3.3 North America Chronic Thromboembolic Pulmonary Hypertension Clinical Trials by Country
3.4 Middle East and Africa Chronic Thromboembolic Pulmonary Hypertension Clinical Trials by Country
3.5 South and Central America Chronic Thromboembolic Pulmonary Hypertension Clinical Trials by Country

4. Chronic Thromboembolic Pulmonary Hypertension Clinical Trial Trends
4.1 Start Year wise Chronic Thromboembolic Pulmonary Hypertension Clinical Trials
4.2 Phase wise Chronic Thromboembolic Pulmonary Hypertension Clinical Trials
4.3 Trial Status wise Chronic Thromboembolic Pulmonary Hypertension Clinical Trials
4.4 Trial Type wise Chronic Thromboembolic Pulmonary Hypertension Clinical Trials

5. Chronic Thromboembolic Pulmonary Hypertension Average Enrollment Trends
5.1 Average Enrollment in Chronic Thromboembolic Pulmonary Hypertension Trials by Year
5.2 Average Enrollment in Chronic Thromboembolic Pulmonary Hypertension Trials by Phase
5.3 Average Enrollment in Chronic Thromboembolic Pulmonary Hypertension Trials by Status
5.4 Average Enrollment in Chronic Thromboembolic Pulmonary Hypertension Trials by Type of Trial

6. Companies Participating in Chronic Thromboembolic Pulmonary Hypertension Clinical Trials
6.1 Chronic Thromboembolic Pulmonary Hypertension Trials by Sponsor Type
6.2 Chronic Thromboembolic Pulmonary Hypertension Average Enrollment by Sponsor Type
6.3 Subjects Recruited by Leading Sponsors

7. Trial Snapshots- Phase, Type, Title, Location, Start Year, Completion Year, Recruitment Status, Enrollment, Participating Countries, Trial Locations, Company, Drugs and Other Details
7.1 Chronic Thromboembolic Pulmonary Hypertension Trials- Phase 1
7.2 Chronic Thromboembolic Pulmonary Hypertension Trials- Phase 2
7.3 Chronic Thromboembolic Pulmonary Hypertension Trials- Phase 3
7.4 Chronic Thromboembolic Pulmonary Hypertension Trials- Phase 4

8. Appendix
8.1 Report Guidance
8.2 Research Methodology
8.3 Abbreviations
8.4 Definitions
8.5 Sources
8.6 Publisher Expertise

List of Figures
Figure 1: Chronic Thromboembolic Pulmonary Hypertension Clinical Trials by Region, 2019
Figure 2: Country wise Clinical Trials, 2019
Figure 3: Country wise Average Enrolment, 2019
Figure 4: Asia Pacific - Country wise Chronic Thromboembolic Pulmonary Hypertension Clinical Trials and Enrolment
Figure 5: Europe - Country wise Chronic Thromboembolic Pulmonary Hypertension Clinical Trials and Enrolment
Figure 6: Middle East Africa - Country wise Chronic Thromboembolic Pulmonary Hypertension Clinical Trials and Enrolment
Figure 7: North America - Country wise Chronic Thromboembolic Pulmonary Hypertension Clinical Trials and Enrolment
Figure 8: South and Central America - Country wise Chronic Thromboembolic Pulmonary Hypertension Clinical Trials and Enrolment
Figure 9: Chronic Thromboembolic Pulmonary Hypertension Clinical Trials by Phase
Figure 10: Chronic Thromboembolic Pulmonary Hypertension Clinical Trials by Trial Status
Figure 11: Chronic Thromboembolic Pulmonary Hypertension Clinical Trials by Type
Figure 12: Chronic Thromboembolic Pulmonary Hypertension Clinical Trials by Sponsor Type
Figure 13: Chronic Thromboembolic Pulmonary Hypertension Clinical Trials by Leading Sponsors
Figure 14: Chronic Thromboembolic Pulmonary Hypertension Average Enrollment by Phase
Figure 15: Chronic Thromboembolic Pulmonary Hypertension Average Enrollment by Trial Status
Figure 16: Chronic Thromboembolic Pulmonary Hypertension Average Enrollment by Type
Figure 17: Chronic Thromboembolic Pulmonary Hypertension- Average Enrolment by Type of Sponsors
Figure 18: Chronic Thromboembolic Pulmonary Hypertension- Enrolment by Leading Sponsors
Figure 19: Research Methodology

List of Tables
Table 1: Chronic Thromboembolic Pulmonary Hypertension Clinical Trials Snapshot- 2019
Table 2: Trials by Region, 2019
Table 3: Country wise Clinical Trials and Average Enrolment by Country, 2019
Table 4: Asia Pacific - Country wise Chronic Thromboembolic Pulmonary Hypertension Clinical Trials and Enrolment
Table 5: Europe - Country wise Chronic Thromboembolic Pulmonary Hypertension Clinical Trials and Enrolment
Table 6: Middle East Africa - Country wise Chronic Thromboembolic Pulmonary Hypertension Clinical Trials and Enrolment
Table 7: North America - Country wise Chronic Thromboembolic Pulmonary Hypertension Clinical Trials and Enrolment
Table 8: South and Central America - Country wise Chronic Thromboembolic Pulmonary Hypertension Clinical Trials and Enrolment
Table 9: Clinical Trials by Phase
Table 10: Clinical Trials by Trial Status
Table 11: Clinical Trials by Type
Table 12: Clinical Trials by Sponsor Type
Table 13: Clinical Trials by Leading Sponsors
Table 14: Chronic Thromboembolic Pulmonary Hypertension Average Enrollment by Phase
Table 15: Chronic Thromboembolic Pulmonary Hypertension Average Enrollment by Trial Status
Table 16: Chronic Thromboembolic Pulmonary Hypertension Average Enrollment by Type
Table 17: Chronic Thromboembolic Pulmonary Hypertension- Average Enrolment by Type of Sponsors
Table 18: Chronic Thromboembolic Pulmonary Hypertension- Enrolment by Leading Sponsors
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Bayer AG
  • Daiichi Sankyo Company Ltd
  • Gilead Sciences Inc
  • GlaxoSmithKline Plc
  • Johnson & Johnson
  • Medical Research Network GmbH
  • Nippon Shinyaku Co Ltd
  • Promedica International
  • Scipharm SaRL
  • Sun Pharmaceutical Industries Ltd
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Order Online - visit: https://www.researchandmarkets.com/reports/4767786
Adroll
adroll